Posted by Michael Wonder on 23 Aug 2023
Enhertu approved in Japan as first HER2 directed therapy for patients with HER2 mutant metastatic non-small-cell lung cancer
23 August 2023 - Approval based on DESTINY-Lung02 results showing Enhertu demonstrated a clinically meaningful tumour response of 53.8% in patients with HER2 mutant non-small cell lung cancer.
Daiichi Sankyo today announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with unresectable advanced or recurrent non-small cell lung cancer with HER2 (ERBB2) mutations that has progressed after chemotherapy.
